Enabling Discovery, Development, and Translation of Treatments for Cognitive Dysfunction in Depression Workshop Summary (2015) / Chapter Skim
Currently Skimming:
Appendix B: Workshop Agenda
Appendix B: Workshop Agenda
Pages 65-72
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 65... ...
Moreover, there is a lack of alignment in the scientific field on the best way to assess cognitive dysfunction and whether this dimension is congruent with, or independent from, mood symptoms. There is also an opportunity in this domain to look beyond the classical definition of major depressive disorder and consider approaches involving neurocircuitry and precision medicine.
|
From page 66... ...
8:30 a.m. Opening Remarks THOMAS INSEL, Workshop Co-Chair Director National Institute of Mental Health THOMAS LAUGHREN, Workshop Co-Chair Director Laughren Psychopharm Consulting, LLC SESSION I: BACKGROUND AND OVERVIEW Session Objectives: Provide an overview of the unmet medical need of cognitive dysfunction in depression.
|
From page 67... ...
MICHAEL GREEN Professor-in-Residence Department of Psychiatry and Biobehavioral Sciences Geffen School of Medicine, University of California, Los Angeles 10:15 a.m. BREAK SESSION II: STATE OF THE SCIENCE FOR TREATING COGNITIVE DYSFUNCTION IN DEPRESSION Session Objectives: Examine the current state of the science for treating cognitive dysfunction in depression, including what aspects of this dysfunction can be treated with medications, cognitive behavioral therapy, devices, and other treatment modalities.
|
From page 68... ...
Discussion Among Panelists and Workshop Participants 12:00 p.m. LUNCH SESSION III: DESIGN AND ASSESSMENT CHALLENGES Session Objectives: Examine opportunities and challenges in studying and assessing treatments for cognitive dysfunction in depression, including combination therapies.
|
From page 69... ...
12:45 p.m. Opening Remarks MADHUKAR TRIVEDI, Session Moderator Betty Jo Hay Distinguished Chair in Mental Health University of Texas Southwestern Medical Center 12:50 p.m.
|
From page 70... ...
Food and Drug Administration Perspective: Drugs TIFFANY FARCHIONE Acting Deputy Director Division of Psychiatry Products Food and Drug Administration 2:45 p.m. Food and Drug Administration Perspective: Devices CARLOS PEÑA Director, Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health Food and Drug Administration 2:55 p.m.
|
From page 71... ...
Hackett, M.D., Endowed Chair in Psychiatry Massachusetts General Hospital AMIT ETKIN Assistant Professor of Psychiatry and Behavioral Sciences Stanford University MADHUKAR TRIVEDI Betty Jo Hay Distinguished Chair in Mental Health University of Texas Southwestern Medical Center THOMAS LAUGHREN Director Laughren Psychopharm Consulting, LLC 4:40 p.m. Discussion Among Panelists and Workshop Participants 5:15 p.m.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.